Cardlytics, Inc. $CDLX Stock Position Increased by Check Capital Management Inc. CA

Check Capital Management Inc. CA lifted its position in Cardlytics, Inc. (NASDAQ:CDLX) by 20.7% during the second quarter, Holdings Channel reports. The institutional investor owned 74,500 shares of the company’s stock after buying an additional 12,800 shares during the quarter. Check Capital Management Inc. CA’s holdings in Cardlytics were worth $123,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Lane Generational LLC bought a new stake in shares of Cardlytics in the 1st quarter worth $1,109,000. Deutsche Bank AG raised its position in shares of Cardlytics by 123.8% during the first quarter. Deutsche Bank AG now owns 48,728 shares of the company’s stock worth $89,000 after purchasing an additional 26,958 shares during the period. LPL Financial LLC raised its position in shares of Cardlytics by 30.3% during the first quarter. LPL Financial LLC now owns 859,406 shares of the company’s stock worth $1,564,000 after purchasing an additional 200,087 shares during the period. Invesco Ltd. raised its position in shares of Cardlytics by 34.2% during the first quarter. Invesco Ltd. now owns 97,054 shares of the company’s stock worth $177,000 after purchasing an additional 24,731 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Cardlytics during the first quarter worth $302,000. Institutional investors own 68.10% of the company’s stock.

Cardlytics Stock Performance

Shares of CDLX stock opened at $1.91 on Friday. The company has a debt-to-equity ratio of 2.87, a current ratio of 1.16 and a quick ratio of 1.16. Cardlytics, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $5.24. The stock’s 50-day moving average is $1.59 and its two-hundred day moving average is $1.72. The firm has a market cap of $101.69 million, a P/E ratio of -0.52 and a beta of 1.45.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CDLX. Evercore ISI cut their target price on Cardlytics from $3.00 to $2.00 and set an “in-line” rating on the stock in a research report on Friday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cardlytics in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.25.

Insiders Place Their Bets

In other Cardlytics news, CEO Amit Gupta sold 68,685 shares of the company’s stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $1.12, for a total value of $76,927.20. Following the transaction, the chief executive officer directly owned 491,759 shares of the company’s stock, valued at $550,770.08. This represents a 12.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 159,335 shares of company stock valued at $204,204. Corporate insiders own 4.40% of the company’s stock.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.